Francesco Pichi1,2, Ahmed Mohammed Elbarky3, Tarek Roshdy Elhamaky3. 1. Eye Institute, Cleveland Clinic Abu Dhabi, PO Box 112412, Al Maryiah Island, Abu Dhabi, UAE. ilmiticopicchio@gmail.com. 2. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA. ilmiticopicchio@gmail.com. 3. Faculty of Medicine, Benha University, Banha, Egypt.
Abstract
PURPOSE: To compare the efficacy of a modified PRN treatment regimen ("treat and monitor") of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. METHODS:Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a "treat and monitor" treatment regimen with monthly follow-up for 12 months. Primary outcome measures included mean change in best corrected visual acuity (BCVA) and central foveal thickness (CFT) at month 12 compared to baseline. RESULTS: At 12 months follow-up, the mean BCVA improved from 0.58 ± 0.13 to 0.20 ± 0.15 logMAR (P = 0.0003) in the aflibercept group (mean injections 2.6 ± 1.51) and from 0.52 ± 0.11 to 0.21 ± 0.1 logMAR (P = 0.0002) in the ranibizumab group (mean injections 2.8 ± 1.78). No statistical difference between the two groups in terms of the visual acuity gains in eyes with macular edema secondary to non-ischemic BRVO treated with either aflibercept or ranibizumab was observed. Mean CFT reduced from 498 ± 46 to 204 ± 23 µm (P < 0.0001) in the aflibercept group and from 488 ± 31 to 212 ± 29 µm (P < 0.0001) in the ranibizumab group. CONCLUSION: "Treat and monitor" regimen is a real-life effective strategy in improving visual acuity after macular edema from branch vein occlusion and in reducing the number of injections.
RCT Entities:
PURPOSE: To compare the efficacy of a modified PRN treatment regimen ("treat and monitor") of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. METHODS: Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a "treat and monitor" treatment regimen with monthly follow-up for 12 months. Primary outcome measures included mean change in best corrected visual acuity (BCVA) and central foveal thickness (CFT) at month 12 compared to baseline. RESULTS: At 12 months follow-up, the mean BCVA improved from 0.58 ± 0.13 to 0.20 ± 0.15 logMAR (P = 0.0003) in the aflibercept group (mean injections 2.6 ± 1.51) and from 0.52 ± 0.11 to 0.21 ± 0.1 logMAR (P = 0.0002) in the ranibizumab group (mean injections 2.8 ± 1.78). No statistical difference between the two groups in terms of the visual acuity gains in eyes with macular edema secondary to non-ischemic BRVO treated with either aflibercept or ranibizumab was observed. Mean CFT reduced from 498 ± 46 to 204 ± 23 µm (P < 0.0001) in the aflibercept group and from 488 ± 31 to 212 ± 29 µm (P < 0.0001) in the ranibizumab group. CONCLUSION: "Treat and monitor" regimen is a real-life effective strategy in improving visual acuity after macular edema from branch vein occlusion and in reducing the number of injections.
Authors: Rachel L McIntosh; Sophie L Rogers; Lyndell Lim; Ning Cheung; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep P Nguyen; Tien Yin Wong Journal: Ophthalmology Date: 2010-06 Impact factor: 12.079
Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079
Authors: H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima Journal: Eye (Lond) Date: 2006-07-07 Impact factor: 3.775
Authors: Peter A Campochiaro; Jeffrey S Heier; Leonard Feiner; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2010-04-15 Impact factor: 12.079
Authors: Sophie Rogers; Rachel L McIntosh; Ning Cheung; Lyndell Lim; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep Nguyen; Tien Y Wong Journal: Ophthalmology Date: 2010-02 Impact factor: 12.079
Authors: David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2011-08 Impact factor: 12.079